Recent News Releases

As we approach the OPTIONS XII for the Control of Influenza, a global scientific meeting that focuses on influenza, there is an enormous sense of pride among all of us at CSL Seqirus. For the...

Veltassa® offers effective and well-tolerated long-term potassium control in chronic kidney disease and chronic heart failure patients 1-5 Zeria Pharmaceutical Co., Ltd. to market Veltassa® in Japan

Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to protect public health KOSTAIVE®,...

CSL Seqirus to provide 665,000 pre-pandemic (zoonotic) vaccines to support fifteen EU and EEA Member States. Outbreaks of highly pathogenic avian influenza (HPAI) viruses in birds and poultry have...

Throughout 2023 and 2024, outbreaks of highly pathogenic avian influenza (HPAI) viruses among birds have been reported in several regions including Africa, Asia, Europe, and North America...

Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results add to recently published data on ARCT-154 demonstrating superior...

Under the licensing and distribution agreement, CSL Seqirus will be responsible for applying for regulatory approval, reimbursement and commercialisation of neffyTM (adrenaline nasal spray) ARS...

First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically...

Australia’s newest biotech incubator Jumar Bioincubator has officially opened its doors and revealed the first 16 innovative early-stage ventures to take up residency in its much-awaited Melbourne-based facility at an event officiated by Lord Mayor, Sally Capp AO.

CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of...